文献速递肥胖与代谢综合征糖尿病

肝脏脂肪介导减重所致血清肝因子变化:一项随机对照试验

Contribution of Liver Fat to Weight Loss-Induced Changes in Serum Hepatokines: A Randomized Controlled Trial.
PubMed 文献 · J Clin Endocrinol Metab · 2019-01-01

本研究纳入25名瘦男性与52名腹型肥胖男性,后者随机接受8周饮食减重或无减重干预。减重使IGF1、IGFBP1、SHBG和胎球蛋白A趋近瘦男性水平,中介分析显示仅IGF1变化由肝内甘油三酯介导(32.7%)。

要点

  • 减重对肝因子影响各异,IGF1、IGFBP1、SHBG和胎球蛋白A改善。
  • 肝内甘油三酯介导了减重后IGF1变化的32.7%。
  • 肝因子或为肥胖相关共病的潜在介质。

核心结论

  • 饮食减重对肝因子有不同影响,减重后血清IGF1变化由肝内甘油三酯变化介导。

研究设计与样本

  • 横断面研究加随机对照试验,纳入瘦男性25名和腹型肥胖男性52名。
  • 腹型肥胖男性随机接受8周饮食减重或不减重干预。

主要发现

  • 除胎球蛋白B外,瘦男性与肥胖男性间所有肝因子有显著差异。
  • 减重干预后平均减重-10.3 kg(95%CI -11.4至-9.2),IGF1、IGFBP1、SHBG和胎球蛋白A趋近瘦男性水平。
  • 横断面分析中,肝内甘油三酯与IGF1(β=-0.51;95%CI -0.82至-0.20)、IGFBP1(β=-4.2;95%CI -7.7至-0.7)和FGF21(β=2.1;95%CI 1.3至2.9)相关。
  • 减重使肝内甘油三酯降低(治疗效应-2.2%;95%CI -3.4%至-1.2%),并与IGF1(β=-0.9;95%CI -1.3至-0.4)、IGFBP1(β=-0.17;95%CI -0.31至-0.03)和SHBG(β=-0.18;95%CI -0.29至-0.07)变化相关。
  • 中介分析显示仅减重所致血清IGF1变化由肝内甘油三酯介导(介导效应32.7%;95%CI 4.6%至79.2%)。

临床怎么用

  • 减重改善肝因子谱,部分效应通过减少肝内甘油三酯实现。
  • 监测肝内甘油三酯可能有助于理解减重对IGF1等肝因子的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Hepatokines have emerged as potential mediators of obesity-associated comorbidities, such as type 2 diabetes, cardiovascular disease, fractures, and central hypogonadism. OBJECTIVE: To assess whether weight loss-induced changes in hepatokines are mediated by intrahepatic triglyceride (IHTG) content. DESIGN: Cross-sectional study and randomized controlled trial. SETTING: General community. PARTICIPANTS: Metabolically healthy, lean men (waist <94 cm; n = 25) and men with abdominal obesity (waist 102 to 110 cm; n = 52). INTERVENTION: Men with abdominal obesity were randomized to 8-week dietary weight loss or no weight loss. MAIN OUTCOME MEASURES: IHTG and serum hepatokines, that is, serum IGF1, IGF binding protein 1 (IGFBP1), SHBG, fibroblast growth factor 21 (FGF21), fetuin A, and plasma fetuin B. RESULTS: All hepatokines, except for fetuin B, were significantly different between lean men and men with obesity. After the weight-loss intervention (-10.3 kg; 95% CI, -11.4 to-9.2), serum IGF1, IGFBP1, SHBG, and fetuin A approached the values observed in lean men. Cross-sectional associations were observed between IHTG and IGF1 (β = -0.51; 95% CI, -0.82 to -0.20), IGFBP1 (β = -4.2; 95% CI, -7.7 to -0.7), and FGF21 (β = 2.1; 95% CI, 1.3 to 2.9) in lean men and men with abdominal obesity combined. Weight loss resulted in a reduction of IHTG (treatment effect, -2.2%; 95% CI, -3.4% to -1.2%) that was associated with a change in IGF1 (β = -0.9; 95% CI, -1.3 to -0.4), IGFBP1 (β = -0.17; 95% CI, -0.31 to -0.03), and SHBG levels (β = -0.18; 95% CI, -0.29 to -0.07). Mediation analyses showed that only the weight loss-induced change in serum IGF1 was mediated by IHTG (mediated effect, 32.7%; 95% CI, 4.6% to 79.2%). CONCLUSIONS: Dietary weight loss has differential effects on hepatokines. This study shows that the change in serum IGF1 levels after dietary weight loss is mediated by the change in IHTG content.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Telgenkamp I, Kusters YHAM, Schalkwijk CG, et al. Contribution of Liver Fat to Weight Loss-Induced Changes in Serum Hepatokines: A Randomized Controlled Trial. J Clin Endocrinol Metab. 2019. PMID: 30753672. doi:10.1210/jc.2018-02378

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。